Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-04-22
2009-12-15
Allen, Marianne P (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000, C435S069100
Reexamination Certificate
active
07632809
ABSTRACT:
The present invention provides compositions and methods for making multimeric proteins to increase stability over their monomer. For example, more stable growth hormone and prolactin receptor agonists are provided.
REFERENCES:
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5681809 (1997-10-01), Kopchick et al.
patent: 5958879 (1999-09-01), Kopchick et al.
patent: 6787336 (2004-09-01), Kopchick et al.
patent: 6875741 (2005-04-01), Pillutla et al.
patent: 2006/0252697 (2006-11-01), Blume et al.
Goffin et al., Journal of Biological Chemistry, 271(28):16573-16579, 1996.
Chawla, R.K., et al., “Structural Variants of Human Growth Hormone”, Ann. Rev. Med. (1983), vol. 34, pp. 519-547.
Edwards, C.K., et al., “A Newly Defined Property of Somatotropin: Priming of Macrophages for Production of Superoxide Anion”, Science, (1988) vol. 239, pp. 769-771.
Venkatachalam, M.A., et al., Energy Thresholds that Determine Membrane Integrity and Injury in a Renal Epithelial Cell Line (LLC-PK1); The Journal of Clinical Investigation (1988) vol. 81, No. 3, pp. 745-758.
Logan, J., et al., “Adenovirus Tripartite Leader Sequence Enhances Translation of mRNAs Late After Infection”, Molecular Endocrinology, (1995) vol. 9, No. 12, pp. 3655-3659.
Altschul, S.F., et al., “Basic Local Alignment Search Tool”, J. Mol. Biol. (1990) vol. 215, pp. 403-410.
Gish, W., et al., “Identification of Protein Coding Regions by Database Similarity Search”, Nature Genetics, (1993), vol. 3, pp. 266-272.
Madden, T.L., et al., “Applications of Network Blast Server”, Methods in Enzymology, (1996), vol. 266, pp. 131-141.
Altschul, S.F., et al., “Gapped Blast and PSI-Blast: A New Generation of Protein Database Search Programs”, Nucleic Acids Research (1997) vol. 25, No. 17, pp. 3389-3402.
Zhang, J., et al., “PowerBlast: A New Network Blast Application for Interactive or Automated Sequence Analysis and Annotation”, Genome Research (1997) vol. 7, pp. 649-656.
Zhang et al., “A Novel Design of Targeted Endocrine and Cytokine Therapy for Breast Cancer,” Vol. 8, 1196-1205, Apr. 2002.
Qiu, H. et al.: “Homodimerization Restores Biological Activity to an Inactive Erythropoietin Mutant”,The Journal of Biological Chemistry, The American Society for Biochemistry and Molecular Biology, Inc. (May 1998), pp. 11173-11176, vol. 273, No. 18, U.S. (XP002453390).
Langenheim, J. F. et al.: “Two Wrongs Can Make a Right: Dimers of Prolactin and Growth Hormone Receptor Antagonists Behave as Agonists”,Molecular Endocrinology, The Endocrine Society (Mar. 2006), pp. 661-674, vol. 20, No. 3, U.S. (XP009089441).
Goffin, V. et al.: “Development of New Prolacting Analogs Acting as Pure Prolactin Receptor Anatgonists”,Pituitary, Kluwer Academic Publishers (Jun. 2003), pp. 89-95, vol. 6, No. 2, U.S. (XP019214353).
Chen, N.Y. et al.: “In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R”,International Journal of Oncology, Editorial Academy Of The International Journal Of Oncology (Jan. 2002), pp. 813-818, vol. 20, U.S. (XP002993163).
Chen, W. Y. et al.: “a Human Prolactin Antagonist, hPRL-G129R, Inhibits Breast Cancer Cell Proliferation through Induction of Apoptosis1”,Clinical Cancer Research, The American Association For Cancer Research (Nov. 1999), pp. 3583-3593, vol. 5, No. 11, U.S. (XP002276493).
Cataldo, L. et al.: “Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells”,International Journal of Oncology, Oncology Research Institute (Dec. 2000), pp. 1179-1185, vol. 17, No. 6, U.S. (XP009089739).
Sytkowski, A. J. et al.: “An Erythropoietin Fusion Protein Comprised of Identical Repeating Domains Exhibits Enhanced Biological Properties”,The Journal of Biological Chemistry, American Society of Biolochemical Biologists (Aug. 1999), pp. 24773-24778, vol. 274, No. 35, U.S. (XP002354910).
Dalle Bruno et al.: “Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo”,Blood, The American Society of Hematology (Jun. 2001), pp. 3776-3782, vol. 97, No. 12, U.S. (XP002453391).
Allen Marianne P
Howrey LLP
Oncolix, Inc.
LandOfFree
Multimeric ligands with enhanced stability does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multimeric ligands with enhanced stability, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multimeric ligands with enhanced stability will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4058653